The role of PI3Kα isoform in cardioprotection

Basic Research in Cardiology

Volumn 112, Issue 6, 2017, Pages

  Rossello, Xavier ^a   Riquelme, Jaime A ^a,b   He, Zhenhe ^a   Taferner, Stasa ^a   Vanhaesebroeck, Bart ^c   Davidson, Sean M ^a   Yellon, Derek M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardioprotection; Ischemia reperfusion injury; Ischemic preconditioning; Phosphoinositide 3 kinase

Indexed keywords

INSULIN; MESSENGER RNA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA ISOFORM; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; ISOENZYME;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CARDIAC MUSCLE CELL; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; GENE EXPRESSION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; ISOLATED HEART; MALE; MITOCHONDRIAL PERMEABILITY; MOUSE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DRUG EFFECT; ENZYMOLOGY; HEART INFARCTION PREVENTION; METABOLISM;

ANIMALS; CARDIOTONIC AGENTS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; ISOENZYMES; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL REPERFUSION INJURY; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 85032859675     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-017-0657-7     Document Type: Article

References (54)

1. Baines CP, Wang L, Cohen MV, Downey JM (1999) Myocardial protection by insulin is dependent on phospatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart. Basic Res Cardiol 94:188–198. doi:10.1007/s003950050142
2. Ban K, Cooper AJ, Samuel S, Bhatti A, Patel M, Izumo S, Penninger JM, Backx PH, Oudit GY, Tsushima RG (2008) Phosphatidylinositol 3-kinase is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res 103:643–653. doi:10.1161/CIRCRESAHA.108.175018
3. Bell RM, Yellon DM (2003) Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35:185–193
4. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H, Dastrù W, Martin EL, Silengo L, Altruda F, Turco E, Lanzetti L, Musiani P, Rückle T, Rommel C, Backer JM, Forni G, Wymann MP, Hirsch E (2008) Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 1:ra3. doi:10.1126/scisignal.1161577
5. Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, Rikova K, Zhao J, Hirsch E, Benes CH, Engelman JA (2015) Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell 27:97–108. doi:10.1016/j.ccell.2014.11.007
6. Crompton M (1999) The mitochondrial permeability transition pore and its role in cell death. Biochem J 341:233–249. doi:10.1042/bj3410233
7. Davidson SM, Hausenloy D, Duchen MR, Yellon DM (2006) Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 38:414–419. doi:10.1016/j.biocel.2005.09.017
8. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, Sancho S, Smith AJH, Withers DJ, Vanhaesebroeck B (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441:366–370. doi:10.1038/nature04694
9. Gent S, Skyschally A, Kleinbongard P, Heusch G (2017) lschemic preconditioning in pigs: a causal role for signal transducer and activator of transcription 3. Am J Physiol Heart Circ Physiol 312:H478–H484. doi:10.1152/ajpheart.00749.2016
10. Ghigo A, Morello F, Perino A, Damilano F, Hirsch E (2011) Specific PI3K isoform modulation in heart failure: lessons from transgenic mice. Curr Heart Fail Rep 8:168–175. doi:10.1007/s11897-011-0059-3
11. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJH, Okkenhaug K, Vanhaesebroeck B (2008) The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA 105:8292–8297. doi:10.1073/pnas.0707761105
12. Hausenloy DJ, Mocanu MM, Yellon DM (2004) Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 63:305–312. doi:10.1016/j.cardiores.2004.04.011
13. Hausenloy DJ, Yellon DM (2007) Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 116:173–191. doi:10.1016/j.pharmthera.2007.06.005
14. Hausenloy DJ, Yellon DM (2007) Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 12:217–234. doi:10.1007/s10741-007-9026-1
15. Heffron TP, Heald RA, Ndubaku C, Wei B, Augistin M, Do S, Edgar K, Eigenbrot C, Friedman L, Gancia E, Jackson PS, Jones G, Kolesnikov A, Lee LB, Lesnick JD, Lewis C, McLean N, Mörtl M, Nonomiya J, Pang J, Price S, Prior WW, Salphati L, Sideris S, Staben ST, Steinbacher S, Tsui V, Wallin J, Sampath D, Olivero AG (2016) The rational design of selective benzoxazepin inhibitors of the α-isoform of phosphoinositide 3-kinase culminating in the identification of (S)-2-((2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1, 4]oxazepin-9-yl)oxy)propanamide (GDC-0326). J Med Chem 59:985–1002. doi:10.1021/acs.jmedchem.5b01483
16. Heusch G (2015) Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 116:674–699. doi:10.1161/CIRCRESAHA.116.305348
17. Heusch G (2017) Critical issues for the translation of cardioprotection. Circ Res 120:1477–1486. doi:10.1161/CIRCRESAHA.117.310820
18. Heusch G, Bøtker HE, Przyklenk K, Redington A, Yellon D (2015) Remote ischemic conditioning. J Am Coll Cardiol 65:177–195. doi:10.1016/j.jacc.2014.10.031
19. Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M (2012) STAT5 activation and cardioprotection by remote ischemic preconditioning in humans. Novelty and significance. Circ Res 110:111–115. doi:10.1161/CIRCRESAHA.111.259556
20. Heusch G, Rassaf T (2016) Time to give up on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning. Circ Res 119:676–695. doi:10.1161/CIRCRESAHA.116.308736
21. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454:776–779. doi:10.1038/nature07091
22. Jonassen AK, Brar BK, Mjøs OD, Sack MN, Latchman DS, Yellon DM (2000) Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 32:757–764. doi:10.1006/jmcc.2000.1118
23. Jonassen AK, Sack MN, Mjøs OD, Yellon DM (2001) Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89:1191–1198. doi:10.1161/hh2401.101385
24. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8:e1000412. doi:10.1371/journal.pbio.1000412
25. Klein HH, Puschmann S, Schaper J, Schaper W (1981) The mechanism of the tetrazolium reaction in identifying experimental myocardial infarction. Virch Arch 393:287–297
26. Kleinbongard P, Heusch G (2015) Extracellular signalling molecules in the ischaemic/reperfused heart—druggable and translatable for cardioprotection? Br J Pharmacol 172:2010–2025. doi:10.1111/bph.12902
27. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM (2006) A pharmacological map of the PI3-K family defines a role for p110? in insulin signaling. Cell 125:733–747. doi:10.1016/j.cell.2006.03.035
28. Lin RCY, Weeks KL, Gao XM, Williams RBH, Bernardo BC, Kiriazis H, Matthews VB, Woodcock EA, Bouwman RD, Mollica JP, Speirs HJ, Dawes IW, Daly RJ, Shioi T, Izumo S, Febbraio MA, Du XJ, McMullen JR (2010) PI3K(p110) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arterioscler Thromb Vasc Biol 30:724–732. doi:10.1161/ATVBAHA.109.201988
29. Lu M-J, Chen Y-S, Huang H-S, Ma M-C (2014) Hypoxic preconditioning protects rat hearts against ischemia-reperfusion injury via the arachidonate12-lipoxygenase/transient receptor potential vanilloid 1 pathway. Basic Res Cardiol 109:414. doi:10.1007/s00395-014-0414-0
30. Lu Z, Jiang Y-P, Wang W, Xu X-H, Mathias RT, Entcheva E, Ballou LM, Cohen IS, Lin RZ (2009) Loss of cardiac phosphoinositide 3-kinase p110 alpha results in contractile dysfunction. Circulation 120:318–325. doi:10.1161/CIRCULATIONAHA.109.873380
31. McLean BA, Zhabyeyev P, Patel VB, Basu R, Parajuli N, DesAulniers J, Murray AG, Kassiri Z, Vanhaesebroeck B, Oudit GY (2015) PI3Kα is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart. Cardiovasc Res 105:292–303. doi:10.1093/cvr/cvv016
32. McMullen JR, Amirahmadi F, Woodcock EA, Schinke-Braun M, Bouwman RD, Hewitt KA, Mollica JP, Zhang L, Zhang Y, Shioi T, Buerger A, Izumo S, Jay PY, Jennings GL (2007) Protective effects of exercise and phosphoinositide 3-kinase(p110) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci 104:612–617. doi:10.1073/pnas.0606663104
33. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, Izumo S (2003) Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100:12355–12360. doi:10.1073/pnas.1934654100
34. Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L (2005) Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 293:437–446. doi:10.1001/jama.293.4.437
35. Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124–1136. doi:10.1161/01.CIR.74.5.1124
36. Oudit GY, Penninger JM (2009) Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 82:250–260. doi:10.1093/cvr/cvp014
37. Pretorius L, Du X-J, Woodcock EA, Kiriazis H, Lin RCY, Marasco S, Medcalf RL, Ming Z, Head GA, Tan JW, Cemerlang N, Sadoshima J, Shioi T, Izumo S, Lukoshkova EV, Dart AM, Jennings GL, McMullen JR (2009) Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol 175:998–1009. doi:10.2353/ajpath.2009.090126
38. Rossello X, Burke N, Stoppe C, Bernhagen J, Davidson SM, Yellon DM (2016) Exogenous administration of recombinant MIF at physiological concentrations failed to attenuate infarct size in a Langendorff perfused isolated mouse heart model. Cardiovasc Drugs Ther 30:445–453. doi:10.1007/s10557-016-6673-2
39. Rossello X, Hall AR, Bell RM, Yellon DM (2015) Characterization of the Langendorff perfused isolated mouse heart model of global ischemia-reperfusion injury: impact of ischemia and reperfusion length on infarct size and LDH release. J Cardiovasc Pharmacol Ther 21:286–295. doi:10.1177/1074248415604462
40. Rossello X, Riquelme JA, Davidson SM, Yellon DM (2017) Role of PI3K in myocardial ischaemic preconditioning: mapping pro-survival cascades at the trigger phase and at reperfusion. J Cell Mol Med. doi:10.1111/jcmm.13394
41. Rossello X, Yellon DM (2016) Cardioprotection: the disconnect between bench and bedside. Circulation 134:574–575. doi:10.1161/CIRCULATIONAHA.116.022829
42. Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D’Agostino RB, Ruthazer R, Atkins JM, Sayah AJ, Levy MK, Richards ME, Aufderheide TP, Braude DA, Pirrallo RG, Doyle DD, Frascone RJ, Kosiak DJ, Leaming JM, Van Gelder CM, Walter G-P, Wayne MA, Woolard RH, Opie LH, Rackley CE, Apstein CS, Udelson JE (2012) Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA 307:1925–1933. doi:10.1001/jama.2012.426
43. Sivaraman V, Hausenloy DJ, Wynne AM, Yellon DM (2010) Preconditioning the diabetic human myocardium. J Cell Mol Med 14:1740–1746. doi:10.1111/j.1582-4934.2009.00796.x
44. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G (2009) Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104:15–18. doi:10.1161/CIRCRESAHA.108.186429
45. Skyschally A, Gent S, Amanakis G, Schulte C, Kleinbongard P, Heusch G (2015) Across-species transfer of protection by remote ischemic preconditioning with species-specific myocardial signal transduction by reperfusion injury salvage kinase and survival activating factor enhancement pathways. Novelty and significance. Circ Res 117:279–288. doi:10.1161/CIRCRESAHA.117.306878
46. Slettom G, Jonassen AK, Dahle GO, Seifert R, Larsen TH, Berge RK, Nordrehaug JE (2017) Insulin postconditioning reduces infarct size in the porcine heart in a dose-dependent manner. J Cardiovasc Pharmacol Ther 22:179–188. doi:10.1177/1074248416657611
47. Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C, De Micheli A (1962) Effects of an intravenous infusion of a potassium–glucose–insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol 9:166–181. doi:10.1016/0002-9149(62)90035-8
48. Soler A, Figueiredo AM, Castel P, Martin L, Monelli E, Angulo-Urarte A, Milà-Guasch M, Viñals F, Baselga J, Casanovas O, Graupera M (2016) Therapeutic benefit of selective inhibition of p110α PI3-kinase in pancreatic neuroendocrine tumors. Clin Cancer Res 22:5805–5817. doi:10.1158/1078-0432.CCR-15-3051
49. Tong H, Rockman HA, Koch WJ, Steenbergen C, Murphy E (2004) G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning. Circ Res 94:1133–1141. doi:10.1161/01.RES.0000126048.32383.6B
50. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC (2005) Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30:194–204. doi:10.1016/j.tibs.2005.02.008
51. Vanhaesebroeck B, Whitehead MA, Piñeiro R (2016) Molecules in medicine mini-review: isoforms of PI3K in biology and disease. J Mol Med (Berl) 94:5–11. doi:10.1007/s00109-015-1352-5
52. Yano N, Tseng A, Zhao TC, Robbins J, Padbury JF, Tseng Y-T (2008) Temporally controlled overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility–a new transgenic model. AJP Hear Circ Physiol 295:H1690–H1694. doi:10.1152/ajpheart.00531.2008
53. Yellon DM, Alkhulaifi AM, Pugsley WB (1993) Preconditioning the human myocardium. Lancet 342:276–277. doi:10.1016/0140-6736(93)91819-8
54. Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121–1135. doi:10.1056/NEJMra071667